HLN vs. HIK, HCM, INDV, AMYT, BMK, APH, AGY, BXP, ANCR, and EAH
Should you be buying Haleon stock or one of its competitors? The main competitors of Haleon include Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Benchmark (BMK), Alliance Pharma (APH), Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), and ECO Animal Health Group (EAH). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Haleon (LON:HLN) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
Haleon pays an annual dividend of GBX 6 per share and has a dividend yield of 1.8%. Hikma Pharmaceuticals pays an annual dividend of GBX 57 per share and has a dividend yield of 3.0%. Haleon pays out 5,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals pays out 8,507.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
33.7% of Haleon shares are held by institutional investors. Comparatively, 37.6% of Hikma Pharmaceuticals shares are held by institutional investors. 18.3% of Haleon shares are held by insiders. Comparatively, 30.6% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Hikma Pharmaceuticals received 788 more outperform votes than Haleon when rated by MarketBeat users. Likewise, 70.56% of users gave Hikma Pharmaceuticals an outperform vote while only 27.78% of users gave Haleon an outperform vote.
Haleon has higher revenue and earnings than Hikma Pharmaceuticals. Haleon is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Haleon and Haleon both had 1 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.91 beat Haleon's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.
Haleon has a net margin of 9.64% compared to Hikma Pharmaceuticals' net margin of 6.61%. Hikma Pharmaceuticals' return on equity of 8.81% beat Haleon's return on equity.
Haleon currently has a consensus target price of GBX 356, suggesting a potential upside of 9.50%. Hikma Pharmaceuticals has a consensus target price of GBX 2,050, suggesting a potential upside of 6.22%. Given Haleon's higher probable upside, analysts clearly believe Haleon is more favorable than Hikma Pharmaceuticals.
Summary
Hikma Pharmaceuticals beats Haleon on 11 of the 17 factors compared between the two stocks.
Get Haleon News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
